Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Long-term Follow-up Study to Evaluate Safety and Immunogenicity of a Chikungunya Virus Virus-like Particle Vaccine (CHIKV VLP) in Healthy Adults and Adolescents After Either a Single or Booster Vaccination Dosing Regimen

NCT06007183 is registered in ClinicalTrials.gov with Bavarian Nordic as lead sponsor.

NCT NCT06007183
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06007183 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Long-term Follow-up Study to Evaluate Safety and Immunogenicity of a Chikungunya Virus Virus-like Particle Vaccine (CHIKV VLP) in Healthy Adults and Adolescents After Either a Single or Booster Vaccination Dosing Regimen
Lead sponsor
Bavarian Nordic
Phase
Phase 3
Overall status
Active, not recruiting
Start date
August 30, 2023
Completion date
February 29, 2028
Enrollment
715 (actual)
Sites
24

Conditions

As the registry lists them; a condition with its own page is linked.

chikungunya virus infection